
Oncologist

No OPD information available
EGFR Positive Lung Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC)
Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
Anal Cancer
Anaplastic Thyroid Cancer
Myositis
Pneumonia
Spasmodic Dysphonia
Tissue Biopsy
Victoria J. Bray is a female healthcare provider who helps patients with different types of cancers like lung cancer, head and neck cancer, and other conditions like pneumonia and myositis. She performs tissue biopsies to diagnose these diseases.
Victoria J. Bray is skilled in treating EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer, Anal Cancer, and more. She uses special techniques to help patients feel better and fight their illnesses.
Patients trust Victoria J. Bray because she communicates well with them. She listens to their concerns and explains things in a way they can understand. Patients feel cared for and supported under her care.
Victoria J. Bray stays updated with the latest medical knowledge and research. This helps her provide the best possible care to her patients. She always wants to learn more to improve her skills.
Victoria J. Bray works well with other medical professionals. She shares knowledge and collaborates with colleagues to give patients the best treatment options. Her teamwork approach benefits patients greatly.
Victoria J. Bray's work has positively impacted many patients' lives. Her dedication and expertise have helped patients fight their diseases and improve their health. She is committed to making a difference in the lives of those she treats.
One of Victoria J. Bray's notable publications is about real-world outcomes of lung cancer patients with specific mutations. She is also involved in a clinical trial to find better treatments for advanced pleural mesothelioma.
Overall, Victoria J. Bray is a caring and knowledgeable healthcare provider who goes above and beyond to help her patients. She is dedicated to improving patient outcomes and making a positive impact in the field of oncology.
Enrollment Status: Active not recruiting
Published: November 07, 2024
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
